People
Rob Dunn, a professor of applied ecology at North Carolina State University in Raleigh recently wrote a book, Never Home Alone. In this book, he describes how millions of microorganisms, bacteria, fungi, viruses, parasites and insects live in your home—and in and on your body.
Vivek Ramaswamy’s Roivant Sciences, the umbrella company to 14 Vant companies, including Datavant, Enzyvant Sciences, Urovant Sciences and others, raised another $200 million in equity financing.
Checkpoint inhibitors are only effective against inflamed tumors, called ‘hot’ tumors. Unfortunately, most tumors are ‘cold’ (not inflamed) and hide from the immune system by appearing to be too similar to normal cells.
UH Expert to Bring Consistency to Corneal Stem Cell Fate
ASLAN Pharmaceuticals announced today the appointment of Robert E. Hoffman as an Independent Non-Executive Director. Mr. Hoffman has more than 20 years of experience in leading and managing global biotechnology companies, and working with a number of public, late-stage oncology companies.
Biopharma companies name new members of their leadership teams. Who made big moves this week?
Gail Maderis, currently president and chief executive officer of South San Francisco-based Antiva Biosciences, has a rock-solid resume.
Cabaletta Bio launched out of the University of Pennsylvania with an exclusive license deal and two multi-year sponsored research agreements. The fledgling biotech company will work on engineered T cell products for B cell-mediated autoimmune disease.
Oxurion NV announced today the appointment of Adrienne Graves, Ph.D., to its board of directors. Dr. Graves will replace Paul Howes, who has been a board member since 2014.
In the wake of a Complete Response Letter issued by the FDA, Trevana, Inc. is slashing one-third of its workforce. On Wednesday, Merrimack Pharmaceuticals also announced it was terminating 60 percent of its staff as the company narrows its research and development focus.
PRESS RELEASES